Immunovant
Immunovant is a clinical-stage biopharmaceutical company developing FcRn inhibitor monoclonal antibody therapies, with lead candidate IMVT-1402 in registrational trials for multiple autoimmune diseases including Graves' disease, myasthenia gravis, CIDP, and refractory rheumatoid arthritis. The pre-revenue company is majority-owned by Roivant Sciences.
- Company typePublic
- Founded2018
- HeadquartersNew York, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Immunovant does
Immunovant, Inc. (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies that inhibit the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies driving autoimmune disease. The company's core technology targets the FcRn pathway, which regulates IgG antibody recycling and levels, with the goal of producing disease-modifying effects across multiple IgG-mediated autoimmune conditions. Immunovant is incorporated in Delaware, headquartered in New York, and maintains operational offices in Durham, North Carolina and Basel, Switzerland (Immunovant Sciences GmbH); it employs between 251 and 500 people and operates as a majority-owned subsidiary of Roivant Sciences, which holds approximately 64.65% ownership as of December 2025.
The company's pipeline centers on IMVT-1402 (imeroprubart), a next-generation FcRn inhibitor being advanced through registrational trials for at least six indications: Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), Sjögren's disease, refractory rheumatoid arthritis, and cutaneous lupus. An earlier FcRn inhibitor, batoclimab, was discontinued after Phase 3 trials in thyroid eye disease failed to meet the primary endpoint in April 2026. IMVT-1402 demonstrated 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates at Week 16 in a Phase 2b trial of 165 highly refractory rheumatoid arthritis patients, and topline data for Graves' disease is expected in 2027. Target markets are substantial: Graves' disease affects an estimated 880,000 US patients with analyst-projected $1 billion-plus US sales potential, the myasthenia gravis market is projected to surpass $16 billion by 2036 across seven major markets, and the CIDP market was valued at approximately $1.78 billion in 2023.
Immunovant has no approved products and does not currently generate revenue from product sales; the company is funded almost entirely by equity capital from public markets, private placements, and repeated strategic investments from parent Roivant Sciences. The cumulative capital base includes a $75 million offering in October 2022, a $450 million public offering in September 2023, a $200 million Roivant investment in February 2024, a $450 million private placement in January 2025, and a $550 million common stock financing in December 2025 — the latter explicitly earmarked to fund the potential launch of IMVT-1402 in Graves' disease. As of May 2026, Immunovant reported $902.1 million in cash with no debt, a Q3 FY2025 net loss of $110.6 million, and a market capitalization of approximately $5.9 billion. Go-to-market activity is currently limited to investor-focused channels (SEC filings, press releases, corporate investor relations) consistent with pre-revenue clinical-stage status; commercial distribution infrastructure has not yet been established.
Immunovant firmographics
Firmographics- Name
- Immunovant
- Legal name
- Immunovant, Inc.
- Website
- https://www.immunovant.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Immunovant is a clinical-stage biopharmaceutical company developing FcRn inhibitor monoclonal antibody therapies, with lead candidate IMVT-1402 in registrational trials for multiple autoimmune diseases including Graves' disease, myasthenia gravis, CIDP, and refractory rheumatoid arthritis. The pre-revenue company is majority-owned by Roivant Sciences.
- Ownership category
- akta.pro rank
Immunovant industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industries
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
Keywords
Where Immunovant is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Immunovant business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Marketing channels4 records
Immunovant product offering
Product offeringCore offering
Immunovant is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies that inhibit the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies driving autoimmune diseases. The company's lead candidate IMVT-1402 (imeroprubart) is being advanced through registrational trials across multiple indications including Graves' disease, myasthenia gravis, CIDP, Sjögren's disease, and refractory rheumatoid arthritis.
Product overview
Immunovant is a clinical-stage biopharmaceutical company developing FcRn inhibitor monoclonal antibody therapies for autoimmune diseases. The company's core product portfolio centers on IMVT-1402 (imeroprubart), a next-generation FcRn inhibitor currently in registrational trials for multiple indications including Graves' disease, rheumatoid arthritis, myasthenia gravis, CIDP, Sjögren's disease, and cutaneous lupus. The company previously advanced batoclimab, an earlier FcRn inhibitor, but discontinued its development after Phase 3 failures in thyroid eye disease. Both drug candidates target IgG antibodies involved in inflammation, leveraging the FcRn pathway to reduce pathogenic IgG levels.
Differentiator
Problem solved
Functional benefit
Products and services
- IMVT-1402 (imeroprubart)
Quantifiable outcome
- 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates at Week 16 in 165 highly refractory RA patients
- +2 more outcomes
Companies that use Immunovant
Customer profileSegments5 records
Ideal customer profiles2 records
Immunovant technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Immunovant partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- HanAll BiopharmaminorHanAll Biopharma is the partner for batoclimab development. Immunovant is reviewing future development plans for batoclimab with HanAll following Phase 3 failures in thyroid eye disease.
Scale indicators7 records
Recent moves5 records
Expansion highlights5 records
Immunovant competitors and assessment
Company assessmentBroad incumbents
- Johnson & Johnson: J&J is advancing nipocalimab, an FcRn inhibitor being studied across multiple autoimmune indications including MG and CIDP, and brings large pharma commercial capabilities and capital that exceed Immunovant's.
- Takeda: Takeda has built a substantial rare-disease and immunology franchise through Shire and subsequent deals, making it a relevant peer for specialty autoimmune commercialization in MG and CIDP-adjacent indications.
- Roche: Roche acquired Telavant from Roivant for $7.25B and is a major autoimmune and rare-disease player. It is comparable both as a competitor in adjacent indications and as a benchmark acquirer of late-stage autoimmune assets.
- Sanofi: Sanofi is a global leader in immunology (Dupixent) and rare autoimmune diseases, providing an incumbent reference point for specialty autoimmune commercialization at scale.
- AstraZeneca (Alexion): Through its Alexion rare-disease franchise, AstraZeneca is a major player in autoimmune neurology and rare immunology and has invested in next-generation FcRn and related modalities.
- Amgen (Horizon Therapeutics): Amgen's acquisition of Horizon Therapeutics brought Tepezza for thyroid eye disease and a rare autoimmune commercial infrastructure. It is a relevant comparable for autoimmune market access and commercial execution.
Direct peers
- argenx: argenx is the lead FcRn inhibitor company, with efgartigimod (Vyvgart) approved in myasthenia gravis and CIDP. It is the most direct competitive peer, addressing the same FcRn mechanism and overlapping indications.
- UCB: UCB markets rozanolixizumab (Rystiggo), an FcRn inhibitor approved for myasthenia gravis, and is advancing additional FcRn programs. It competes head-to-head with Immunovant in the same autoimmune indications.
Emerging players
- Vertex Pharmaceuticals: Vertex is a profitable mid-to-large cap biotech transitioning into specialty/autoimmune adjacencies; it provides a benchmark for late-stage biotech capital allocation and pipeline diversification.
- BioMarin Pharmaceutical: BioMarin is a mid-cap rare-disease biotech focused on genetic and specialty conditions, comparable in stage and scale to Immunovant for pipeline valuation and rare-disease commercialization.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Immunovant social profiles
Digital presenceImmunovant financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immunovant leadership team
Management profileNumber of profiles
Profiles14 records
Immunovant funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immunovant M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immunovant
What does Immunovant do?
Immunovant is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies that inhibit the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies driving autoimmune diseases. The company's lead candidate IMVT-1402 (imeroprubart) is being advanced through registrational trials across multiple indications including Graves' disease, myasthenia gravis, CIDP, Sjögren's disease, and refractory rheumatoid arthritis.
Is Immunovant a public or private company?
Immunovant is a public company. It is classified as public and is currently operating.
When was Immunovant founded?
Immunovant was founded in 2018. It employs 251 to 500 people.
Where is Immunovant based?
Immunovant is headquartered in New York, United States, in the North America region.
Who are Immunovant's main competitors?
Broad incumbents on record are Johnson & Johnson, Takeda, Roche, Sanofi, AstraZeneca (Alexion) and Amgen (Horizon Therapeutics). Direct peers are argenx and UCB. Emerging players are Vertex Pharmaceuticals and BioMarin Pharmaceutical.
Does Immunovant have an API?
No public API is recorded for Immunovant.
What industry is Immunovant in?
Immunovant's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.